Munger Mode rating: 4 out of 5 — Buy. Our own rating from the research report below, on business quality first: moat durability and management, with price separating the top three.
Price used: about $82.11, the Nov 5, 2026 close after the earnings reaction (down about 8% from $89.20). I found this on one source only (StockAnalysis) and could not confirm it with a second quote. Market cap is about $33B on 406.3M shares. We have owned our opinions about animal health for a long time. This is a business with a moat we respect, and it is now being tested in its most profitable corner. The business: Zoetis sells medicines, vaccines and diagnostics for pets and livestock. It earns roughly 24% after-tax returns on the capital it employs. The problem: U.S. companion-animal revenue is shrinking. Q3 U.S. revenue fell 6%, and U.S. companion animal fell 8% (from $1,069M to $980M). Dermatology fell 16% in the quarter. Management has also cut revenue guidance more than once this year.
Recent filings analysed: 8-K (2026-11-05), 10-Q (2026-11-05), 8-K (2026-10-13), 8-K (2026-10-08).
Stock screener · Superinvestor 13F holdings · Analyst sentiment